Abstract 1527P
Background
The FGFR/FGF cascade is a complex intracellular pathway that controls cellular proliferation, tumor growth, angiogenesis, and dissemination. It is implicated in various human cancers including gastric cancer (GC). The FGFR2-amplification in a proportion ranging from 9% to 1.2% worldwide in GC patients. However, previous studies have demonstrated FGFR2-amplification may have poor PFS and OS survival in GC patients. Infigratinib (BGJ398) is a selective ATP-competitive, FGFR1–3 selective oral TKI. We present the data generated from the LB1001-201 trial (NCT05019794) Cohort 1 to evaluate the efficacy and safety of infigratinib monotherapy in previously systemic second-line treated patients harbouring FGFR2 gene amplification.
Methods
Population and eligibility criteria - Failed on prior 2nd -lines treatment or above, locally advanced or metastatic GC/EGJ. FGFR2 gene amplification positive was confirmed via central FISH testing. Adequate organ function and laboratory values. MAPK-MEK or selective FGFR inhibitor treatment-naive. Procedures and treatment - Tumor biopsy or FFPE samples will be tested at the central lab for FGFR2 gene amplification orally infigratinib (125mg, QD) for 3 weeks on, 1 week off in each 28-day cycle; Dose adjustment will be based on drug-related AEs and severity per protocol demanded. Outcomes and assessments - ORR and DCR: Descriptive statistics were used, and an accurate 95% CI was provided. Time-to-event endpoints were summarized using K-M analyses. Safety endpoints were analyzed using frequency and percentage distribution in patients who received at least one dose of infigratinib.
Results
cORR 25.0% (95%CI 8.7, 49.1), DCR 80.0% (95%CI 56.3, 94.3), mDoR 3.8 months (mos) (3.6, NE). mPFS 3.3 mos (95%CI 2.3, 4.5), mOS 8.0 mos (95%CI 4.1, NE). 15/19 patients with tumor shrinkage, the maximum from baseline was -78.5%. ≥ Grade 3 TRAE was 42.9%, most were recoverable. No drug-induced death was reported.
Conclusions
Infigratinib in GC/GEJ patients with FGFR2 gene amplification has shown an inspiring clinical improvement, with acceptable tolerance, which is a potential first TKI regimen that precisely targeting in this population.
Clinical trial identification
NCT05019794.
Editorial acknowledgement
Legal entity responsible for the study
Shanghai LianBio Development Co., Ltd.
Funding
Shanghai LianBio Development Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1508TiP - The 1920-EORTC-BIORADON study: Molecular characterization of non-small cell lung cancer (NSCLC) and indoor radon exposure in Europe
Presenter: Laura Mezquita
Session: Poster session 21
1509TiP - The 1825-EORTC, ALKALINE: Activity of lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with second generation ALK inhibitor
Presenter: Laura Mezquita
Session: Poster session 21
1510TiP - Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant non-small cell lung cancer (NSCLC) according to TP53 mutational status (TEMPLE-2/NCT05785208)
Presenter: Antonio Vitale
Session: Poster session 21
1515P - Maintenance rucaparib after first-line platinum-based chemotherapy in advanced esophagogastric (OG) adenocarcinoma: Interim results from the PLATFORM trial
Presenter: Anderley Gordon
Session: Poster session 21
1518P - Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a phase Ib/II study
Presenter: Keun-Wook Lee
Session: Poster session 21
1520P - Perioperative treatment in resectable gastric cancer with spartalizumab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT): The GASPAR phase II trial
Presenter: Melanie Dos Santos
Session: Poster session 21